Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

Judith S. Hecker; Lavinia Pachzelt; Katharina S. Götze

doi:10.1080/17474086.2021.1968822

Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

Judith S. Hecker, Lavinia Pachzelt, Katharina S. Götze

Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie

Technische Universität München

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

5 Zitate (Scopus)

Originalsprache	Englisch
Seiten (von - bis)	789-793
Seitenumfang	5
Fachzeitschrift	Expert Review of Hematology
Jahrgang	14
Ausgabenummer	9
DOIs	https://doi.org/10.1080/17474086.2021.1968822
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.1080/17474086.2021.1968822

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{ad752597ae12473ba6f7d55a5d01781b,

title = "Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations",

keywords = "Apoptosis, BCL-2, azacitidine, myelodysplastic syndromes, venetoclax",

author = "Hecker, {Judith S.} and Lavinia Pachzelt and G{\"o}tze, {Katharina S.}",

note = "Funding Information: KS G{\"o}tze received research funding from BMS/Celgene, and has participated in advisory boards for BMS/Celgene and Abbvie. All other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. ",

year = "2021",

doi = "10.1080/17474086.2021.1968822",

language = "English",

volume = "14",

pages = "789--793",

journal = "Expert Review of Hematology",

issn = "1747-4086",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

AU - Hecker, Judith S.

AU - Pachzelt, Lavinia

AU - Götze, Katharina S.

N1 - Funding Information: KS Götze received research funding from BMS/Celgene, and has participated in advisory boards for BMS/Celgene and Abbvie. All other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

PY - 2021

Y1 - 2021

KW - Apoptosis

KW - BCL-2

KW - azacitidine

KW - myelodysplastic syndromes

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85113496119&partnerID=8YFLogxK

U2 - 10.1080/17474086.2021.1968822

DO - 10.1080/17474086.2021.1968822

M3 - Article

C2 - 34405747

AN - SCOPUS:85113496119

SN - 1747-4086

VL - 14

SP - 789

EP - 793

JO - Expert Review of Hematology

JF - Expert Review of Hematology

IS - 9

ER -